Trial Profile
Omacor; omega-3-acid ethyl ester 90 (N-3 PUFA) and risk faktors in HIV infected patients treated with HAART with special focus on lipids.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Pronova BioPharma
- 14 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 May 2011 New trial record
- 10 Mar 2008 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).